Adjusted by | HR/SD - | HR/SD Physical/metabolic | HR/SD EU SCORE | HR/SD Framingham |
---|---|---|---|---|
AC24 | Â | Â | Â | Â |
CVD | 1.66 (1.25-2.19)*** | NS | 1.38 (1.02-1.86)* | NS |
CVD/cancer | 1.64 (1.35-2.00)*** | 1.31 (1.06-1.63)* | 1.40 (1.13-1.72)** | 1.29 (1.02-1.63)* |
Area | Â | Â | Â | Â |
CVD | 1.60 (1.16-2.20)** | NS | NS | NS |
CVD/cancer | 1.68 (1.36-2.09)*** | 1.32 (1.04-1.66)* | 1.47 (1.16-1.86)** | 1.34 (1.04-1.72)* |
Sim. Area | Â | Â | Â | Â |
CVD | 2.96 (1.76-4.99)*** | 2.00 (1.15-3.49)* | 2.46 (1.41-4.27)** | 2.27 (1.26-4.09)** |
CVD/cancer | 2.37 (1.73-3.25)*** | 1.68 (1.20-2.34)** | 1.96 (1.40-2.73)*** | 1.79 (1.26-2.54)** |
Thickness% | Â | Â | Â | Â |
CVD | NS | NS | NS | NS |
CVD/cancer | 1.45(1.20-1.75)*** | NS | 1.27 (1.04-1.55)* | NS |
Wall % | Â | Â | Â | Â |
CVD | 1.50 (1.16-1.95)** | NS | NS | NS |
CVD/cancer | 1.60 (1.34-1.91)*** | 1.26 (1.04-1.53)* | 1.42 (1.17-1.73)*** | 1.30 (1.05-1.62)* |
Length% | Â | Â | Â | Â |
CVD | 1.55 (1.18-2.04)** | NS | NS | NS |
CVD/cancer | 1.61 (1.34-1.95)*** | 1.26 (1.03-1.55)* | 1.42 (1.16-1.73)*** | 1.29 (1.03-1.62)* |
NCD | Â | Â | Â | Â |
CVD | 2.44 (1.72-3.48)*** | 1.76 (1.20-2.60)** | 2.20 (1.48-3.26)*** | 2.04 (1.34-3.12)*** |
CVD/cancer | 2.28(1.79-2.90)*** | 1.69 (1.30-2.21)*** | 2.00 (1.53-2.62)*** | 1.86 (1.40-2.47)*** |
MAD factor | Â | Â | Â | Â |
CVD | 3.37 (1.83-6.21)*** | 2.44 (1.22-4.89)* | 3.02 (1.55-5.86)** | 2.85 (1.44-5.64)** |
CVD/cancer | 2.19 (1.58-3.04)*** | 1.58 (1.11-2.26)* | 1.83 (1.29-2.59)*** | 1.74 (1.22-2.48)** |
MACD index | Â | Â | Â | Â |
CVD | 5.22 (2.40-11.36)*** | 3.17 (1.48-6.78)** | 4.36 (1.97-9.66)*** | 4.22 (1.79-9.97)*** |
CVD/cancer | 2.99 (2.05-4.35)*** | 2.01 (1.37-2.95)*** | 2.43 (1.64-3.59)*** | 2.27 (1.51-3.41)*** |